Hikal (BOM:524735) Debt-to-Equity : 0.69 (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Hikal Debt-to-Equity?

Hikal's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹3,921 Mil. Hikal's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹4,255 Mil. Hikal's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹11,877 Mil. Hikal's debt to equity for the quarter that ended in Mar. 2024 was 0.69.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hikal's Debt-to-Equity or its related term are showing as below:

BOM:524735' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.63 Med: 0.83 Max: 1.08
Current: 0.69

During the past 13 years, the highest Debt-to-Equity Ratio of Hikal was 1.08. The lowest was 0.63. And the median was 0.83.

BOM:524735's Debt-to-Equity is ranked worse than
75.77% of 846 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs BOM:524735: 0.69

Hikal Debt-to-Equity Historical Data

The historical data trend for Hikal's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikal Debt-to-Equity Chart

Hikal Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.79

0.65

0.63

0.66

0.69

Hikal Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.66	N/A	0.68	N/A	0.69

Competitive Comparison of Hikal's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Hikal's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hikal's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikal's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hikal's Debt-to-Equity falls into.

Hikal Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hikal's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3921	+	4254.8)	/	11876.6
	=	0.69

Hikal's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3921	+	4254.8)	/	11876.6
	=	0.69

Hikal (BOM:524735) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Hikal Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hikal's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikal (BOM:524735) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikal Ltd (BOM:524735) » Definitions » Debt-to-Equity

Traded in Other Exchanges

HIKAL:India

Address

Great Eastern Chambers, 6th Floor, Sector 11, CBD Belapur, Navi Mumbai, MH, IND, 400 614

Website

https://www.hikal.com

Hikal Ltd manufactures chemical intermediates, specialty chemicals, active pharma ingredients, and contract research activities. Its products are distributed to pharmaceuticals, biotech, agrochemicals, and specialty chemical industries. Its segments include crop protection and pharmaceuticals. The majority of the revenue is derived from the pharmaceutical segment.

Hikal (BOM:524735) Headlines

No Headlines